How to Read What FDA Publishes About a Compounding Pharmacy

The short answer

Once a program names the pharmacy that makes its product, a public record opens up. FDA publishes inspection outcomes, observation forms, letters and recalls for compounding facilities, and much of it is reachable in a few minutes.

The difficulty is not access. It is vocabulary. Several of the words carry a narrower meaning than they appear to, and one of the most quoted pieces of information in this whole record is supplied by the facility itself and has not been checked by anyone.

Reading it well means knowing what each document is, and knowing what a blank space means, which is usually less than people assume.

The two places the record lives

The first is FDA's table of registered outsourcing facilities. It covers facilities registered under section 503B and is refreshed on a weekly update cycle, listing each facility with its contact, its initial and most recent registration dates, its last inspection, and several status columns.

The second is a separate FDA page titled Compounding: Inspections, Recalls, and other Actions, arranged alphabetically. That page is broader in one important way: it carries entries for facilities operating as 503A pharmacies as well, not only registered outsourcing facilities. If a program's pharmacy is a state-licensed compounder rather than an outsourcing facility, this is where a federal record of it would appear.

The two are linked deliberately. FDA notes that a company may own or operate more than one registered outsourcing facility, and that the inspections in the table are tied to the facility at the listed address rather than to the company as a whole. It points readers to the actions page for information about facilities under the same ownership. A clean row therefore describes an address, not necessarily an owner.

What a Form 483 is, in FDA's own words

This is the document most likely to be misread, in both directions.

FDA issues a Form 483 to a firm's management at the conclusion of an inspection when an investigator has observed conditions that in their judgment may constitute violations of the Federal Food, Drug, and Cosmetic Act and related Acts. Observations are made where conditions or practices indicate a product has been adulterated, or is being prepared, packed or held under conditions whereby it may become adulterated or rendered injurious to health.

Then comes the sentence that governs how it should be read. FDA states that the Form 483 does not constitute a final agency determination of whether any condition is in violation of the Act or its regulations. The agency repeats that statement in the footnotes to the outsourcing facility table.

It is considered alongside a written Establishment Inspection Report, the evidence collected on site, and any response the company makes, after which FDA decides what further action is appropriate. Companies are encouraged to respond in writing with a corrective action plan and to implement it.

One more feature matters for anyone counting things. FDA says the Form 483 is not intended to be an all-inclusive list of every possible deviation, does not include observations of questionable or unknown significance at the time of the inspection, and that other objectionable conditions may exist that are not cited. Investigators are instructed to note only what they saw.

So the document is neither a conviction nor a complete audit. It is a contemporaneous list of what an investigator observed and thought significant.

Reading the status columns without over-reading them

The table's action column has a small vocabulary, and FDA defines each term.

Closed means the inspection has been closed without further action. Open means FDA has not determined whether further action will be taken. If an action has been taken it is listed, and FDA names warning letter, seizure and injunction as the possibilities.

Open is the one that invites a wrong reading. It is an absence of a decision, not a pending accusation, and it can sit that way for reasons that have nothing to do with severity.

The inspection date has a definition too, and it is not the day the inspectors arrived. Inspections may run over several days, weeks or longer. The date shown is the date a Form 483 listing the investigators' observations was issued, or, if no Form 483 was issued, the last day of the inspection.

The registration dates have their own mechanics. A registered facility must re-register annually and pay an annual establishment fee, and the registration period runs from the start of October to the end of December each year. A facility that does not re-register and pay in full during that window is removed from the list at the start of the next calendar year. So a facility disappearing from the table has not necessarily been sanctioned. It may simply not have re-registered.

FDA also notes that a newly registered facility is added to the list of facilities it intends to inspect on a risk-based schedule, and that it plans to inspect within a reasonable period after initial registration once it is confirmed the facility has begun production and distribution. Timing is affected by the number of registrants, other inspection priorities, and the facility's operational status. A facility with no inspection listed may simply be new.

The column that is self-reported and unverified

One column in the outsourcing facility table records whether the facility intends to compound sterile drugs from bulk substances. It is the sort of detail that gets quoted as though FDA had established it.

FDA's footnote says otherwise, plainly: the information in that column was provided by the registered outsourcing facility at the time of registration and has not been verified by FDA.

The same footnote defines the blank case. N/A indicates the facility has not provided this information. That is worth holding onto, because a reader scanning quickly will tend to convert N/A into no. It does not mean no. It means nothing was supplied.

This is a good habit to generalize. In this record, an empty cell almost always means unreported, unscheduled or undetermined rather than negative.

Recalls, and why the class matters

FDA treats a recall as a firm's removal or correction of a marketed product that the agency considers to be in violation of the laws it administers and against which it would initiate legal action. Recalls may be conducted on a firm's own initiative, by FDA request, or by FDA order under statutory authority.

Separately from deciding whether something is a recall, FDA classifies it to indicate the relative degree of health hazard. A class I recall is a situation in which there is a reasonable probability that use of or exposure to a violative product will cause serious adverse health consequences or death. A class II recall is one where use may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. A class III recall is one where use is not likely to cause adverse health consequences. A market withdrawal, by contrast, occurs when a product has a minor violation that would not be subject to legal action.

The timing has a trap in it. FDA's enforcement report includes recalls that are not yet classified, and the agency notes that classification is usually determined only after the recalling firm has provided everything needed to assess the risk. Firms often initiate voluntary recalls and issue public statements well before FDA completes classification.

So a recall can be underway, and publicly announced by the company, while the federal record still shows no class. An unclassified recall is not a mild recall. It is an unfinished assessment.

In the outsourcing facility table, FDA explains that a recall flag based on inspectional findings means the inspection revealed significant issues, and that the facility may have initiated a recall itself following conversations with the investigator, or FDA may have recommended one at the conclusion of the inspection, or both. It also notes a facility may have conducted multiple recalls or recalled multiple drugs, so one flag is not necessarily one event.

The gap in the federal record

Here is the limit that matters most for a reader comparing programs, and FDA states it directly: the outsourcing facility table does not include State Board of Pharmacy actions.

FDA's instruction is to check with the State Board of Pharmacy for the state where the facility is located to determine whether it has been the subject of a state enforcement action, and it notes that some states post disciplinary or other actions on their websites.

That gap is large, because a state board is the primary day-to-day regulator of a pharmacy compounding under section 503A. A facility can have an unremarkable federal row and a state history, and nothing in the federal table would show it.

The alphabetical actions page narrows the gap a little, since its entries include referral letters FDA has sent to state boards of pharmacy alongside inspection observations and letters. A referral is a sign the federal and state records are connected, and a prompt to go look at the state one.

A search worth knowing about

FDA points out one search on the actions page that is directly relevant to anyone buying through an online program rather than from a pharmacy directly.

Searching the term telehealth in FDA's Warning Letter Database returns warning letters issued to telehealth companies. That is a different question from whether a pharmacy has a record, and for a reader whose relationship is with a website rather than a compounder, it may be the more useful one.

Read whatever comes back for its actual subject. A letter about how a product was promoted is a different thing from a letter about how it was made, and the existence of a letter is a disclosure rather than a verdict.

What this is good for, and what it is not

Used well, this record answers a narrow question honestly: what has FDA observed and done at this named facility, at this address, as of the last update.

It does not tell you whether a product is good. It does not rank facilities, and it cannot, since inspection timing varies with priorities and registrant numbers rather than with quality. It says nothing about state actions unless a referral happens to appear.

Its real value is that it converts a name into checkable facts, which is precisely why the name is the thing worth insisting on. A program that will not tell you which facility makes its product has made every document described here unreachable.